A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
NCT ID: NCT02121522
Last Updated: 2016-06-27
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
14 participants
INTERVENTIONAL
2014-06-30
2015-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD)
NCT03861234
A Study to Evaluate the Efficacy and Safety of IBI302inSubjects With nAMD
NCT07275840
Trial to Evaluate the Safety and Tolerability of Repeated Intravitreal Injection of IBI302 in Neovascular AMD Patients
NCT04370379
Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)
NCT00320788
Intravitreal Faricimab in Patients With Refractory Macular Edema
NCT07093385
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BI 144807
twice daily
BI 144807
twice daily
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BI 144807
twice daily
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Boehringer Ingelheim
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Boehringer Ingelheim
Role: STUDY_CHAIR
Boehringer Ingelheim
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
1313.20.43001 Boehringer Ingelheim Investigational Site
Vienna, , Austria
1313.20.49004 Boehringer Ingelheim Investigational Site
Bonn, , Germany
1313.20.49002 Boehringer Ingelheim Investigational Site
Leipzig, , Germany
1313.20.49001 Boehringer Ingelheim Investigational Site
Lübeck, , Germany
1313.20.49005 Boehringer Ingelheim Investigational Site
Münster, , Germany
1313.20.49003 Boehringer Ingelheim Investigational Site
Tübingen, , Germany
1313.20.49006 Boehringer Ingelheim Investigational Site
Ulm, , Germany
1313.20.36002 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1313.20.36003 Boehringer Ingelheim Investigational Site
Budapest, , Hungary
1313.20.36001 Boehringer Ingelheim Investigational Site
Debrecen, , Hungary
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-004567-30
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
1313.20
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.